Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2021 | BiTEs in the early treatment of multiple myeloma

Hareth Nahi, MD, PhD, of the Karolinska Institutet, Stockholm, Sweden, discusses the latest data on the use of bispecific T-cell engagers (BiTEs) in the treatment of multiple myeloma. Dr Nahi recommends that BiTEs are used as early as possible in the treatment of myeloma, commenting on data from Phase I and II studies which report response rates to other drugs of 20-35%, in comparison to response rates of 65-85% for patients with relapsed or refractory myeloma receiving BiTEs. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.

Transcript (edited for clarity)

I will try to discuss the position of the T-cell’s engagement in myeloma treatment in the near future. My recommendation will be to use them as early as possible. And the argumentation that I have, one, looking at historical data in single-agent myeloma drugs in Phase I to II studies, the response rates are between 20 to 35%, as to say, one-third of the patient will respond to, so, new single-agent myeloma drug...

I will try to discuss the position of the T-cell’s engagement in myeloma treatment in the near future. My recommendation will be to use them as early as possible. And the argumentation that I have, one, looking at historical data in single-agent myeloma drugs in Phase I to II studies, the response rates are between 20 to 35%, as to say, one-third of the patient will respond to, so, new single-agent myeloma drug.

While looking at these T-cell engager, we are using them in a very late stage patient. Often, they are refractory and penta-exposed. We see a response rate between 65, up to 85, as to say, they are very effective. And I will argue to use these drugs as early as possible, and try to minimize the time taken for this agent to reach the first-line treatment, but because I believe the most effective agents should be used in first-line in cancer patients.

Read more...